RARE

MEDIA ADVISORY: Ultragenyx Announces Mepsevii® (vestronidase alfa) Receives Reimbursement Approval for Treatment of Mucopolysaccharidosis VII in Spain

Ultragenyx Appoints Corsee Sanders, Ph.D., to Board of Directors

Ultragenyx Pharmaceuticals Analyst Turns Bullish: What Investors Need To Know

GeneTx and Ultragenyx Receive Approval from U.K. Regulatory Agency to Begin Clinical Study of GTX-102 for the Treatment of Angelman Syndrome

Ultragenyx to Present at Goldman Sachs 42nd Annual Healthcare Conference

Ultragenyx to Present at Jefferies Virtual Healthcare Conference

GeneTx Bio-Ultragenyx's Angelman Syndrome Study To Start Enrollment In Canada